

Claims

1. A method of modulating production of an amyloidogenic peptide comprising contacting a cell which is expressing:
 - a) the precursor from which the amyloidogenic peptide is derived; and
 - 5 b) a Nogo polypeptide with a Nogo antagonist.
2. A method according to claim 1 wherein the precursor is APP.
- 10 3. A method according to claim 1 or 2 wherein the amyloidogenic peptide is A β .
4. A method according to any one of claims 1 to 3 wherein the Nogo polypeptide is NogoA.
- 15 5. A method according to any one of claims 1 to 4 wherein the Nogo antagonist is a monoclonal antibody.
6. A method according to claim 5 wherein the monoclonal antibody is a function-blocking anti-NogoA monoclonal antibody.
- 20 7. Use of a Nogo antagonist in the manufacture of a medicament for the treatment or prophylaxis of a disease involving amyloidosis.
- 25 8. Use according to claim 7 wherein the amyloidosis is precipitated by an amyloidogenic peptide derived from APP.
9. Use according to claim 8 wherein the amyloidogenic peptide is A β .
- 30 10. Use according to any one of claims 7 to 9 wherein the disease is Alzheimer's disease.
11. Use according to any one of claims 7 to 10 wherein the Nogo antagonist is a NogoA antagonist.
- 35 12. Use according to claim 11 wherein the NogoA antagonist is a monoclonal antibody.

13. Use according to claim 12 wherein the monoclonal antibody is a function-blocking anti-NogoA antibody.

14. Use according to claim 13 wherein the function-blocking anti-Nogo antibody is an antibody which binds to a region of human Nogo between 586 to 785 (NogoA amino acid numbering).

15. Use according to claim 12 wherein the anti-NogoA antibody comprises one or more of the following CDRs:

Light chain CDRs

CDR	According to Kabat
L1	RSSKSLLYKDGKTYLN (SEQ ID NO:1)
L2	LMSTRAS (SEQ ID NO:2)
L3	QQLVEYPLT (SEQ ID NO:3)

Heavy chain CDRs

CDR	According to Kabat
H1	SYWMH (SEQ ID NO:4)
H2	NINPSNGGTNYNEKFKS (SEQ ID NO:5)
H3	GQGY (SEQ ID NO:6)

16. Use according to claim 12 wherein the anti-NogoA antibody comprises one or more of the following CDRs:

Light chain CDRs

CDR	According to Kabat
L1	RSSQSLVHSNGNTYLH (SEQ ID NO:7)
L2	KVSNRFS (SEQ ID NO:8)
L3	SQSTHVPLT (SEQ ID NO:9)

Heavy chain CDRs

CDR	According to Kabat
H1	FSCYAMS (SEQ ID NO:10)
H2	SISDGGSYTYYPDENVKG (SEQ ID NO:11)
H3	ELLFDY (SEQ ID NO:12)

17. Use according to claim 12 wherein the anti-NogoA antibody comprises
 5 one or more of the following CDRs:

Light chain CDRs

CDR	According to Kabat
L1	RSSKSLHNSNGNTYLY (SEQ ID NO:13)
L2	RMSNLAS (SEQ ID NO:14)
L3	MQHLEYPLT (SEQ ID NO:15)

Heavy chain CDRs

10

CDR	According to Kabat
H1	SYWMN (SEQ ID NO:16)
H2	QIYPGDGDTNYNGKFKG (SEQ ID NO:17)
H3	RFDY (SEQ ID NO:18)

18. Use according to claim 12 wherein the monoclonal antibody is a
 15 humanised antibody.
19. A method of treatment or prophylaxis of Alzheimer's disease
 which comprises administering to said human in need thereof an effective
 amount of an anti-Nogo antibody as defined in any one of claims 13 to 18.